Latest public offering nets $601mm for bluebird bio

19:41 EDT 25 Jul 2018 | Elsevier Business Intelligence

Immunotherapy and gene editing firm bluebird bio Inc. netted $601mm through the public offering of 3.9mm common shares (inclu...

Original Article: Latest public offering nets $601mm for bluebird bio


More From BioPortfolio on "Latest public offering nets $601mm for bluebird bio"

Quick Search


Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...